Kelley Dacus

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin-6 (IL-6) inhibitor, is the only FDA-approved treatment for adult patients with iMCD. Limited...

Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study

Background Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that is associated with a broad range of symptoms, including constitutional, gastrointestinal, neuropsychiatric, dermatologic, respiratory, and hematologic or lymphoreticular proble...